Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.72 USD | -8.70% | -9.06% | -9.92% |
Mar. 22 | Lyra Therapeutics Files $300 Million Mixed Shelf Offering | MT |
Mar. 21 | Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 88
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Integrated Drug and Drug Delivery Solutions
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +14.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 2 | 100.0 % | +14.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Jason Cavalier
DFI | Director of Finance/CFO | 51 | 21-09-12 |
Richard Nieman
CTO | Chief Tech/Sci/R&D Officer | 61 | 22-07-10 |
Vineeta Belanger
CTO | Chief Tech/Sci/R&D Officer | - | 19-08-31 |
John Bishop
CTO | Chief Tech/Sci/R&D Officer | 62 | 23-02-26 |
Ellen Cavaleri
IRC | Investor Relations Contact | - | 21-12-31 |
Ronan O’Brien
LAW | General Counsel | 52 | 23-10-15 |
Corinne Noyes
PRN | Corporate Officer/Principal | 56 | 18-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Harlan Waksal
CHM | Chairman | 71 | 22-02-15 |
W. Smith
BRD | Director/Board Member | 68 | 19-11-18 |
James Tobin
BRD | Director/Board Member | 79 | 22-03-06 |
C. Merrifield
BRD | Director/Board Member | 73 | 19-09-03 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 20-10-27 |
Michael Altman
BRD | Director/Board Member | 42 | 18-05-31 |
Maria Palasis
CEO | Chief Executive Officer | 59 | 14-12-31 |
Director/Board Member | 40 | 20-01-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,743,123 | 46,281,091 ( 77.47 %) | 0 | 77.47 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.92% | 282M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LYRA Stock
- Company Lyra Therapeutics, Inc.